BACKGROUND: The resting motor threshold (rMT) is an important factor in the selection of treatment intensity for patients receivingrepetitive transcranial magnetic stimulation (rTMS). In many clinical studies to date, due to concerns about potential drift, the rMT has been routinely re-measured weekly or every fifth session. OBJECTIVE: Our aim is to investigate whether ongoing treatment with rTMS affects the rMT, the degree of change, and whether frequent remeasurement is needed. METHODS: Clinical data were drawn from 50 medication free patients receiving treatment for major depression with rTMS in a large U.S. NIH-sponsored multisite study. Four measurements of rMT were obtained including before and after the double blind phase, followed by weekly measurements during the open phase. Active treatment consisted of 75 four second trains of 10Hz stimulation applied over 37.5 minutes with the coil over the left DLPFC at 120% rMT. RESULTS: For the group as a whole, there was no significant change in the rMT during a minimum of 2 weeks of treatment with prefrontal rTMS (p=0.911, one way ANOVA). The average within-subject coefficient of variation was 6.58%. On average the last rMT was 2.45% less than the baseline rMT (range 32.3% increase, 40.6% decrease). CONCLUSION: Daily left prefrontal rTMS over several weeks as delivered in this trial does not cause systematic changes in rMT. While most subjects had <10% variance in rMT over time, 5 subjects had changes of approximately 20% from baseline, raising dosing and safety issues if undetected. We recommend that clinical trials of rTMS have periodic retesting of rMT, especially if the dose is at or near the edge of the TMS safety tables.
RCT Entities:
BACKGROUND: The resting motor threshold (rMT) is an important factor in the selection of treatment intensity for patients receiving repetitive transcranial magnetic stimulation (rTMS). In many clinical studies to date, due to concerns about potential drift, the rMT has been routinely re-measured weekly or every fifth session. OBJECTIVE: Our aim is to investigate whether ongoing treatment with rTMS affects the rMT, the degree of change, and whether frequent remeasurement is needed. METHODS: Clinical data were drawn from 50 medication free patients receiving treatment for major depression with rTMS in a large U.S. NIH-sponsored multisite study. Four measurements of rMT were obtained including before and after the double blind phase, followed by weekly measurements during the open phase. Active treatment consisted of 75 four second trains of 10Hz stimulation applied over 37.5 minutes with the coil over the left DLPFC at 120% rMT. RESULTS: For the group as a whole, there was no significant change in the rMT during a minimum of 2 weeks of treatment with prefrontal rTMS (p=0.911, one way ANOVA). The average within-subject coefficient of variation was 6.58%. On average the last rMT was 2.45% less than the baseline rMT (range 32.3% increase, 40.6% decrease). CONCLUSION: Daily left prefrontal rTMS over several weeks as delivered in this trial does not cause systematic changes in rMT. While most subjects had <10% variance in rMT over time, 5 subjects had changes of approximately 20% from baseline, raising dosing and safety issues if undetected. We recommend that clinical trials of rTMS have periodic retesting of rMT, especially if the dose is at or near the edge of the TMS safety tables.
Authors: David H Avery; Paul E Holtzheimer; Walid Fawaz; Joan Russo; John Neumaier; David L Dunner; David R Haynor; Keith H Claypoole; Chandra Wajdik; Peter Roy-Byrne Journal: Biol Psychiatry Date: 2005-09-01 Impact factor: 13.382
Authors: W J Triggs; K J McCoy; R Greer; F Rossi; D Bowers; S Kortenkamp; S E Nadeau; K M Heilman; W K Goodman Journal: Biol Psychiatry Date: 1999-06-01 Impact factor: 13.382
Authors: Walter Paulus; Joseph Classen; Leonardo G Cohen; Charles H Large; Vincenzo Di Lazzaro; Michael Nitsche; Alvaro Pascual-Leone; F Rosenow; John C Rothwell; Ulf Ziemann Journal: Brain Stimul Date: 2008-06-30 Impact factor: 8.955
Authors: John P O'Reardon; H Brent Solvason; Philip G Janicak; Shirlene Sampson; Keith E Isenberg; Ziad Nahas; William M McDonald; David Avery; Paul B Fitzgerald; Colleen Loo; Mark A Demitrack; Mark S George; Harold A Sackeim Journal: Biol Psychiatry Date: 2007-06-14 Impact factor: 13.382
Authors: V K Kimiskidis; S Papagiannopoulos; D A Kazis; K Sotirakoglou; G Vasiliadis; F Zara; A Kazis; K R Mills Journal: Exp Brain Res Date: 2006-03-09 Impact factor: 1.972
Authors: Kevin A Johnson; Mirza Baig; Dave Ramsey; Sarah H Lisanby; David Avery; William M McDonald; Xingbao Li; Elisabeth R Bernhardt; David R Haynor; Paul E Holtzheimer; Harold A Sackeim; Mark S George; Ziad Nahas Journal: Brain Stimul Date: 2012-03-14 Impact factor: 8.955
Authors: Shawn M McClintock; Irving M Reti; Linda L Carpenter; William M McDonald; Marc Dubin; Stephan F Taylor; Ian A Cook; John O'Reardon; Mustafa M Husain; Christopher Wall; Andrew D Krystal; Shirlene M Sampson; Oscar Morales; Brent G Nelson; Vassilios Latoussakis; Mark S George; Sarah H Lisanby Journal: J Clin Psychiatry Date: 2018 Jan/Feb Impact factor: 4.384
Authors: Tarique Perera; Mark S George; Geoffrey Grammer; Philip G Janicak; Alvaro Pascual-Leone; Theodore S Wirecki Journal: Brain Stimul Date: 2016-03-16 Impact factor: 8.955
Authors: Helge H Müller; Udo Reulbach; Juan Manuel Maler; Johannes Kornhuber; Wolfgang Sperling Journal: J Neural Transm (Vienna) Date: 2013-06-05 Impact factor: 3.575
Authors: Martin Schecklmann; Michael Landgrebe; Tobias Kleinjung; Elmar Frank; Philipp G Sand; Rainer Rupprecht; Peter Eichhammer; Göran Hajak; Berthold Langguth Journal: BMC Neurosci Date: 2014-06-04 Impact factor: 3.288